Edition:
United Kingdom

Ipsen SA (IPN.PA)

IPN.PA on Paris Stock Exchange

119.55EUR
22 Mar 2019
Change (% chg)

€-2.35 (-1.93%)
Prev Close
€121.90
Open
€122.50
Day's High
€122.95
Day's Low
€119.55
Volume
95,244
Avg. Vol
106,233
52-wk High
€155.95
52-wk Low
€107.50

Latest Key Developments (Source: Significant Developments)

Ipsen To Acquire Clementia Pharmaceuticals
Monday, 25 Feb 2019 

Feb 25 (Reuters) - IPSEN SA ::IPSEN TO ACQUIRE CLEMENTIA PHARMACEUTICALS TO SIGNIFICANTLY BOOST RARE DISEASE PORTFOLIO.IPSEN TO ACQUIRE ALL OUTSTANDING SHARES OF CLEMENTIA FOR A PURCHASE PRICE OF US$25.00 PER SHARE IN CASH UPFRONT PLUS A CONTINGENT VALUE RIGHT (CVR) OF US$6.00 PER SHARE.  Full Article

Ipsen FY Group Net Sales Rise To 2.22 Billion Euros
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - IPSEN SA ::IPSEN DELIVERS STRONG 2018 RESULTS AND EXPECTS CONTINUED SALES AND PROFIT GROWTH IN 2019.FY GROUP NET SALES REACHED EUR 2,224.8 MILLION, UP 20.1% YEAR-ON-YEAR..CORE OPERATING INCOME REACHED EUR 659.9 MILLION IN 2018, COMPARED TO EUR 503.6 MILLION IN 2017, A GROWTH OF 31.0%.CORE CONSOLIDATED NET PROFIT WAS EUR 491.6 MILLION IN 2018, AN INCREASE OF 35.5% VERSUS EUR 362.7 MILLION IN 2017.SEES 2019 GROUP SALES GROWTH YEAR-ON-YEAR AT CONSTANT CURRENCY GREATER THAN +13.0%.SEES 2019 CORE OPERATING MARGIN AROUND 31.0% OF NET SALES.  Full Article

Ipsen And 3BP Announce First Patient Dosed In IPN01087 Phase I/II Study
Tuesday, 20 Nov 2018 

Nov 20 (Reuters) - IPSEN SA ::IPSEN AND 3BP ANNOUNCE FIRST PATIENT DOSED IN PHASE I/II STUDY FOR FIRST-IN-CLASS RADIONUCLIDE (IPN01087).KEY OBJECTIVE OF PHASE I DOSE-ESCALATION TRIAL (EUDRACT NUMBER 2017-001263-20) IS TO EVALUATE SAFETY AND ACTIVITY.IPN01087 IS A COMPOUND THAT TARGETS CANCER CELLS IN PATIENTS WITH ADVANCED SOLID TUMORS WHICH EXPRESS NEUROTENSIN RECEPTOR SUBTYPE 1 (NTSR1).  Full Article

Ipsen Delivers Strong Sales Growth Of 20.2%1 For The Q3 2018 And Confirms Full Year Guidance
Thursday, 25 Oct 2018 

Oct 25 (Reuters) - Ipsen SA ::IPSEN DELIVERS STRONG SALES GROWTH OF 20.2%1 FOR THE THIRD QUARTER OF 2018 AND CONFIRMS FULL YEAR GUIDANCE.Q3 2018 GROUP SALES GROWTH OF 20.2%.FULL YEAR 2018 GUIDANCE CONFIRMED.FULL YEAR 2018 GUIDANCE CONFIRMED WITH GROUP SALES GROWTH OF GREATER THAN 19.0%1 AND CORE OPERATING MARGIN OF AROUND 29.0% OF SALES.Q3 GROUP SALES EUR 555.9 MILLION VERSUS EUR 470.1 MILLION YEAR AGO.  Full Article

Ipsen Receives Positive CHMP Opinion For Cabometyx
Friday, 21 Sep 2018 

Sept 21 (Reuters) - IPSEN SA ::IPSEN RECEIVES POSITIVE CHMP OPINION FOR CABOMETYX (CABOZANTINIB) FOR THE SECOND-LINE TREATMENT OF PATIENTS WITH HEPATOCELLULAR CARCINOMA (HCC).CHMP POSITIVE OPINION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION (EC).  Full Article

Ipsen Raises FY Guidance
Thursday, 26 Jul 2018 

July 26 (Reuters) - Ipsen SA ::H1 OPERATING INCOME EUR 269.7 MILLION VERSUS EUR 176.4 MILLION YEAR AGO.H1 CONSOLIDATED NET PROFIT EUR 197.3 MILLION VERSUS EUR 125.9 MILLION YEAR AGO.UPGRADED FULL YEAR 2018 GUIDANCE OF GROUP SALES GROWTH GREATER THAN 19.0%(1) (VERSUS PRIOR GUIDANCE GREATER THAN 16.0%) AND CORE OPERATING MARGIN OF AROUND 29.0% OF SALES (VERSUS PRIOR GUIDANCE GREATER THAN 28.0%).  Full Article

Ipsen’s Cabometyx receives approval from European Commission
Thursday, 17 May 2018 

May 17 (Reuters) - IPSEN SA ::EUROPEAN COMMISSION APPROVES IPSEN’S CABOMETYX® (CABOZANTINIB) FOR THE FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA.EC APPROVED CABOMETYX (CABOZANTINIB) 20, 40, 60 MG FOR FIRST-LINE TREATMENT OF ADULTS WITH INTERMEDIATE- OR POOR-RISK ARCC.THIS APPROVAL ALLOWS FOR MARKETING OF CABOMETYX (CABOZANTINIB) IN THIS INDICATION IN ALL 28 MEMBER STATES OF EUROPEAN UNION, NORWAY AND ICELAND.  Full Article

Ipsen And Exelixis Announce Phase 3 Trial Results Of Cabozantinib Showing Benefit In Hepatocellular Carcinoma Patients
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - IPSEN SA ::EXELIXIS AND IPSEN ANNOUNCE PHASE 3 TRIAL RESULTS OF CABOZANTINIB DEMONSTRATING SIGNIFICANT OVERALL SURVIVAL BENEFIT IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA.IN CELESTIAL, CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT VERSUS PLACEBO IN OVERALL SURVIVAL.MEDIAN OS WAS 10.2 MONTHS WITH CABOZANTINIB VERSUS 8.0 MONTHS WITH PLACEBO.  Full Article

Ipsen Appoints Richard Paulson Executive VP And CEO Of Ipsen North America
Friday, 12 Jan 2018 

Jan 12 (Reuters) - IPSEN SA ::IPSEN APPOINTS RICHARD PAULSON EXECUTIVE VICE-PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IPSEN NORTH AMERICA.  Full Article

Ipsen ‍Announces Results From Phase III Study of Dysport On Neurology​
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - IPSEN SA ::‍ANNOUNCED RESULTS FROM PHASE III STUDY DEMONSTRATING EFFICACY AND SAFETY OF DYSPORT(ABOBOTULINUMTOXINA) IN ADULT PATIENTS ​.‍STUDY WAS IN ADULT PATIENTS WITH LOWER LIMB SPASTICITY FOLLOWING A STROKE OR TRAUMATIC BRAIN INJURY​.‍MOST COMMON ADVERSE REACTIONS WERE: FALLS, MUSCULAR WEAKNESS, AND PAIN IN EXTREMITY​.‍WHILE MAJORITY OF PATIENTS WERE RE-TREATED AT WEEK 12, WERE TREATED AT WEEK 16 AND BEYOND​.  Full Article

PRESS DIGEST- Canada- Feb 26

Feb 26 The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.